Phase Holographic Imaging PHI AB (publ)
Phase Holographic Imaging PHI AB (publ), a medical technology company, develops and markets non-invasive time-lapse imaging instruments in Sweden and internationally. The company's products include HoloMonitor, a live cell imaging system; HoloMonitor app Suite for cell imaging software facilitates kinetic live cell tracking and analysis; HoloMonitor M4FL, a system for fluorescence; and HoloMonito… Read more
Phase Holographic Imaging PHI AB (publ) (L5W) - Net Assets
Latest net assets as of October 2025: €32.73 Million EUR
Based on the latest financial reports, Phase Holographic Imaging PHI AB (publ) (L5W) has net assets worth €32.73 Million EUR as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€36.91 Million) and total liabilities (€4.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €32.73 Million |
| % of Total Assets | 88.65% |
| Annual Growth Rate | 21.78% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 428.63 |
Phase Holographic Imaging PHI AB (publ) - Net Assets Trend (2022–2025)
This chart illustrates how Phase Holographic Imaging PHI AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Phase Holographic Imaging PHI AB (publ) (2022–2025)
The table below shows the annual net assets of Phase Holographic Imaging PHI AB (publ) from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-04-30 | €48.74 Million | +877.11% |
| 2024-04-30 | €4.99 Million | +33.80% |
| 2023-04-30 | €3.73 Million | -86.18% |
| 2022-04-30 | €26.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Phase Holographic Imaging PHI AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €48.74 Million | 100.00% |
| Total Equity | €48.74 Million | 100.00% |
Phase Holographic Imaging PHI AB (publ) Competitors by Market Cap
The table below lists competitors of Phase Holographic Imaging PHI AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hrvatska Postanska Banka d.d.
ZSE:HPB
|
$2.69 Million |
|
Playgon Games Inc
PINK:PLGNF
|
$2.69 Million |
|
Real Good Food Company Inc
NASDAQ:RGF
|
$2.69 Million |
|
Nusa Palapa Gemilang PT Tbk
JK:NPGF
|
$2.70 Million |
|
Grande Asset Hotels and Property Public Company Limited
BK:GRAND
|
$2.69 Million |
|
Western Yilgarn NL
AU:WYX
|
$2.69 Million |
|
Logiq Inc
PINK:LGIQ
|
$2.69 Million |
|
Winvia Entertainment PLC
LSE:WVIA
|
$2.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Phase Holographic Imaging PHI AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,988,000 to 48,738,000, a change of 43,750,000 (877.1%).
- Net loss of 17,519,000 reduced equity.
- New share issuances of 59,535,000 increased equity.
- Other factors increased equity by 1,734,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-17.52 Million | -35.95% |
| Share Issuances | €59.53 Million | +122.15% |
| Other Changes | €1.73 Million | +3.56% |
| Total Change | €- | 877.11% |
Book Value vs Market Value Analysis
This analysis compares Phase Holographic Imaging PHI AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.06x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-04-30 | €1.87 | €0.04 | x |
| 2023-04-30 | €0.18 | €0.04 | x |
| 2024-04-30 | €0.19 | €0.04 | x |
| 2025-04-30 | €0.77 | €0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Phase Holographic Imaging PHI AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -105.24%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.15x
- Recent ROE (-35.95%) is above the historical average (-289.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -94.06% | -310.70% | 0.14x | 2.14x | €-28.08 Million |
| 2023 | -621.92% | -234.19% | 0.29x | 9.31x | €-23.56 Million |
| 2024 | -404.47% | -191.96% | 0.32x | 6.62x | €-20.67 Million |
| 2025 | -35.95% | -105.24% | 0.30x | 1.15x | €-22.39 Million |
Industry Comparison
This section compares Phase Holographic Imaging PHI AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $253,026,393
- Average return on equity (ROE) among peers: -74.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Phase Holographic Imaging PHI AB (publ) (L5W) | €32.73 Million | -94.06% | 0.13x | $2.69 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $17.10 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.23 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.77 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.77 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $610.05 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.55 Million |